| Code | CSB-RA007690MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to reference antibody AB-598, targeting ENTPD1 (ectonucleoside triphosphate diphosphohydrolase-1), also known as CD39. ENTPD1 is a cell surface enzyme that catalyzes the sequential hydrolysis of extracellular ATP and ADP to adenosine monophosphate, playing a critical role in purinergic signaling and immune regulation. By controlling extracellular nucleotide levels, ENTPD1 modulates inflammatory responses, T cell activation, and platelet aggregation. This enzyme has significant implications in cancer immunology, where it contributes to the immunosuppressive tumor microenvironment, as well as in cardiovascular disease, transplant rejection, and autoimmune disorders.
The reference antibody AB-598 has been utilized in research investigating ENTPD1 expression patterns and functional roles across various cell types, particularly in immune cell populations and tumor-infiltrating lymphocytes. This biosimilar antibody serves as a valuable tool for researchers studying purinergic signaling pathways, immune checkpoint mechanisms, and therapeutic strategies targeting the adenosine axis in cancer and inflammatory diseases.
There are currently no reviews for this product.